Europe Virology Market to Grow at a CAGR of 3.4% to reach US$ 1,521.97 million from 2021 to 2028

Europe Virology Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Diagnostic Test, Viral Infection Controlling Techniques, Antiviral Therapeutics, and Interferons), Application (Skin and Soft Tissue Infections, Respiratory Tract Infections, GI Tract Infections, Sexually Transmitted Diseases, Urinary Tract Infection, and Others), and End User (Hospitals, Diagnostic Laboratories, Pharmaceutical and Biotechnological Companies, and Research and Academic Institutes)

  • Report Code : TIPRE00025736
  • Category : Biotechnology
  • Status : Published
  • No. of Pages : 202
Buy Now

The virology market in Europe is expected to grow from US$ 1,208.26 million in 2021 to US$ 1,521.97 million by 2028; it is estimated to grow at a CAGR of 3.4% from 2021 to 2028.

The UK, Germany, France, Italy, and Spain are major economies in Europe. Virology is among the significant sections of the healthcare system. It has an extensive application in vaccine development, diagnostics, treatment therapies, and others. The market players are constantly involved in product innovations and developments to sustain the competition in the market. They explore various scopes for product innovations.

For instance, for COVID-19, market players are investing significantly in the development of vaccines, testing kits, and other related products and services. Below are a few of the market developments related to the virology market:
  • In August 2021, the U.S. Food and Drug Administration (FDA) approved the first COVID-19 vaccine known as the Pfizer-BioNTech COVID-19 Vaccine. It will be marketed as ComiRNAty (Koe-mir’-na-tee). The vaccine is intended to prevent COVID-19 disease in individuals aged 16 years and above. It is also available under emergency use authorization (EUA).
  • In April 2021, CerTest Biotec launched its CE-marked COVID-19 diagnostic test for the BD MAX System.
  • In May 2020, Bio-Rad received FDA approval for emergency use authorization for the COVID-19 total antibody test.
  • In May 2020, Aalto Bio Reagents launched New Recombinant Eukaryotic SARS-CoV-2 S1-S2 Spike Proteins.

Thus, such active participation of the market players by product innovations and favourable governments support is expected to bolster the growth of the Europe virology market.

Emerging virus epidemics occur unexpectedly and demand rapid action to stop the disease from spreading. The most recent outbreak of COVID-19 worldwide highlights the need developing diagnostics, vaccines, and antiviral drugs on an urgent basis. As COVID-19 belongs to the coronavirus family, much research into MERS and the development of vaccines against it enabled the rapid advancement of vaccines against COVID-19. Therefore, developing prototype vaccines against potential viruses could greatly accelerate the development of vaccines against any emerging pandemic. For instance, Before COVID-19, The Coalition for Epidemic Preparedness Innovations (CEPI) had developed a robust portfolio of MERS vaccine candidates and invested more than US$140 million to MERS vaccine development, which later laid the groundwork for rapid response to COVID-19 and enabled rapid COVID-19 vaccine development, including the Oxford vaccine. Also, CEPI established a collaboration with the University of Oxford in 2018 to develop a vaccine against MERS using their ChadOx vaccine platform. CEPI provided additional funding to the University of Oxford to adapt this platform technology to develop a vaccine against COVID-19. To scale the manufacture of their COVID-19 vaccine candidate, the University of Oxford subsequently partnered with AstraZeneca, who committed to producing the vaccine on a non-profit basis during the pandemic. Therefore, the pandemic preparedness has helped launch vaccines in a short period, further emphasizing the need for more investment in emerging virus’s research. Europe has been investing in the research of emerging viruses for a long time. The Centre has contributed expertise to recent Ebola outbreaks and is now working on COVID-19. In addition, Vaccine approvals have raised hopes of eventually overcoming the pandemic. However, recent outbreaks and the emergence of new strains of the virus affect the economic outcomes, and a post-pandemic will require governments and the private sector to make long-lasting commitments to global epidemic and pandemic preparedness.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive virology market. The Europe virology market is expected to grow at a good CAGR during the forecast period.

 Europe virology market
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

Europe Virology Market Segmentation

Europe Virology Market – By Type

  • Diagnostic Test
    • DNA Virus Testing
    • RNA Virus Testing
    • Others
  • Viral Infection Controlling Techniques
    • Active Prophylaxis
    • Passive Prophylaxis
  • Antiviral Therapeutics
    • Virucidal Agents
    • Antiviral Agents
    • Immunomodulators
  • Interferons

Europe Virology Market – By Application

  • Skin and Soft Tissue Infections
  • Respiratory Tract Infections
  • GI Tract Infections
  • Sexually Transmitted Diseases
  • Urinary Tract Infections
  • Others

Europe Virology Market – By End User

  • Hospitals
  • Diagnostic Laboratories
  • Pharmaceutical and Biotechnological Companies
  • Research and Academic Institutes

Europe Virology Market- By Country

  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe

Europe Virology Market-Companies Mentioned

  • Abbott
  • AbbVie Inc.
  • F. HOFFMANN-LA ROCHE LTD.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline Plc
  • Illumina, Inc.
  • Johnson and Johnson Services, Inc.
  • QIAGEN
  • Siemens AG
  • THERMO FISHER SCIENTIFIC INC.
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

TABLE OF CONTENTS

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 Europe Virology Market – By Type

1.3.2 Europe Virology Market – By Application

1.3.3 Europe Virology Market – By End User

1.3.4 Europe Virology Market– By Country

2. Europe Virology Market – Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Europe Virology Market– Market Landscape

4.1 Overview

4.2 Europe PEST Analysis

4.3 Experts Opinion

5. Europe Virology Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Growing Prevalence of Viral Infectious Diseases

5.1.2 Increasing Product Launches

5.2 Market Restraints

5.2.1 Availability of Alternative Products and High Cost of Production of Products

5.3 Market Opportunities

5.3.1 Growth Potential in Several Economies

5.4 Future Trends

5.4.1 Continuous Demand for Cost-Effective Products

5.5 Impact Analysis

6. Virology Market– Europe Analysis

6.1 Europe Virology Market Revenue Forecast and Analysis

7. Europe Virology Market Analysis – By Type

7.1 Overview

7.2 Europe Virology Market Revenue Share, by Type (2021 and 2028)

7.3 Diagnostic Test

7.3.1 Overview

7.3.2 Diagnostic Test: Virology Market – Revenue and Forecast to 2028 (US$ Million)

7.3.2.1 Deoxyribonucleic Acid (DNA) Virus Testing

7.3.2.1.1 Overview

7.3.2.1.2 DNA Virus Testing: Virology Market – Revenue and Forecast to 2028 (US$ Million)

7.3.2.2 Ribonucleic Acid (RNA) Virus Testing

7.3.2.2.1 Overview

7.3.2.2.2 RNA Virus Testing: Virology Market – Revenue and Forecast to 2028 (US$ Million)

7.3.2.3 Others

7.3.2.3.1 Overview

7.3.2.3.2 Others: Virology Market – Revenue and Forecast to 2028 (US$ Million)

7.4 Viral Infection Controlling Techniques

7.4.1 Overview

7.4.2 Viral Infection Controlling Techniques: Virology Market – Revenue and Forecast to 2028 (US$ Million)

7.4.2.1 Active Prophylaxis

7.4.2.1.1 Overview

7.4.2.1.2 Active Prophylaxis: Virology Market – Revenue and Forecast to 2028 (US$ Million)

7.4.2.2 Passive Prophylaxis

7.4.2.2.1 Overview

7.4.2.2.2 Passive Prophylaxis: Virology Market – Revenue and Forecast to 2028 (US$ Million)

7.5 Antiviral Therapeutics

7.5.1 Overview

7.5.2 Antiviral Therapeutics: Virology Market – Revenue and Forecast to 2028 (US$ Million)

7.5.2.1 Virucidal Agents

7.5.2.1.1 Overview

7.5.2.1.2 Virucidal Agents: Virology Market – Revenue and Forecast to 2028 (US$ Million)

7.5.2.2 Antiviral Agents

7.5.2.2.1 Overview

7.5.2.2.2 Antiviral Agents: Virology Market – Revenue and Forecast to 2028 (US$ Million)

7.5.2.3 Immunomodulators

7.5.2.3.1 Overview

7.5.2.3.2 Immunomodulators: Virology Market – Revenue and Forecast to 2028 (US$ Million)

7.6 Interferons

7.6.1 Overview

7.6.2 Interferons: Virology Market – Revenue and Forecast to 2028 (US$ Million)

8. Europe Virology Market Analysis – By Application

8.1 Overview

8.2 Europe Virology Market, by Application 2021 & 2028 (%)

8.3 Skin and Soft Tissue Infections

8.3.1 Overview

8.3.2 Skin and Soft Tissue Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)

8.4 Respiratory Tract Infections

8.4.1 Overview

8.4.2 Respiratory Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)

8.5 GI Tract Infections

8.5.1 Overview

8.5.2 GI Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)

8.6 Sexually Transmitted Diseases

8.6.1 Overview

8.6.2 Sexually Transmitted Diseases: Virology Market – Revenue and Forecast to 2028 (US$ Million)

8.7 Urinary Tract Infections

8.7.1 Overview

8.7.2 Urinary Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)

8.8 Others

8.8.1 Overview

8.8.2 Others: Virology Market – Revenue and Forecast to 2028 (US$ Million)

9. Europe Virology Market Analysis – By End User

9.1 Overview

9.2 Europe Virology Market Revenue Share, by End User (2021 and 2028)

9.3 Hospitals

9.3.1 Overview

9.3.2 Hospitals: Virology Market – Revenue and Forecast to 2028 (US$ Million)

9.4 Diagnostic Laboratories

9.4.1 Overview

9.4.2 Diagnostic Laboratories: Virology Market – Revenue and Forecast to 2028 (US$ Million)

9.5 Pharmaceutical and Biotechnological Companies

9.5.1 Overview

9.5.2 Pharmaceutical and Biotechnological Companies: Virology Market – Revenue and Forecast to 2028 (US$ Million)

9.6 Research and Academic Institutes

9.6.1 Overview

9.6.2 Research and Academic Institutes: Virology Market – Revenue and Forecast to 2028 (US$ Million)

10. Europe Virology Market – Country Analysis

10.1.1 Europe Virology Market Revenue and Forecasts to 2028, By Country (%)

10.1.1.1 UK Virology Market Revenue and Forecasts to 2028 (US$ million)

10.1.1.1.1 UK Virology Market Revenue and Forecasts to 2028 (US$ million)

10.1.1.1.2 UK Virology Market Revenue and Forecasts to 2028, By Type (US$ million)

10.1.1.1.2.1 UK: Virology Market, by Diagnostic Test, 2019–2028 (USD Million)

10.1.1.1.2.2 UK: Virology Market, by Viral Infection Controlling Techniques, 2019–2028 (USD Million)

10.1.1.1.2.3 UK: Virology Market, by Antiviral Therapeutics, 2019–2028 (USD Million)

10.1.1.1.3 UK Virology Market Revenue and Forecasts to 2028, by Application (US$ million)

10.1.1.1.4 UK Virology Market Revenue and Forecasts to 2028, by End User (US$ million)

10.1.1.2 Germany Virology Market Revenue and Forecasts to 2028 (US$ million)

10.1.1.2.1 Germany Virology Market Revenue and Forecasts to 2028 (US$ million)

10.1.1.2.2 Germany Virology Market Revenue and Forecasts to 2028, By Type (US$ million)

10.1.1.2.2.1 Germany: Virology Market, by Diagnostic Test, 2019–2028 (USD Million)

10.1.1.2.2.2 Germany: Virology Market, by Viral Infection Controlling Techniques, 2019–2028 (USD Million)

10.1.1.2.2.3 Germany: Virology Market, by Antiviral Therapeutics, 2019–2028 (USD Million)

10.1.1.2.3 Germany Virology Market Revenue and Forecasts to 2028, by Application (US$ million)

10.1.1.2.4 Germany Virology Market Revenue and Forecasts to 2028, by End User (US$ million)

10.1.1.3 France Virology Market Revenue and Forecasts to 2028 (US$ million)

10.1.1.3.1 France Virology Market Revenue and Forecasts to 2028 (US$ million)

10.1.1.3.2 France Virology Market Revenue and Forecasts to 2028, By Type (US$ million)

10.1.1.3.2.1 France: Virology Market, by Diagnostic Test, 2019–2028 (USD Million)

10.1.1.3.2.2 France: Virology Market, by Viral Infection Controlling Techniques, 2019–2028 (USD Million)

10.1.1.3.2.3 France: Virology Market, by Antiviral Therapeutics, 2019–2028 (USD Million)

10.1.1.3.3 France Virology Market Revenue and Forecasts to 2028, by Application (US$ million)

10.1.1.3.4 France Virology Market Revenue and Forecasts to 2028, by End User (US$ million)

10.1.1.4 Italy Virology Market Revenue and Forecasts to 2028 (US$ million)

10.1.1.4.1 Italy Virology Market Revenue and Forecasts to 2028 (US$ million)

10.1.1.4.2 Italy Virology Market Revenue and Forecasts to 2028, By Type (US$ million)

10.1.1.4.2.1 Italy: Virology Market, by Diagnostic Test, 2019–2028 (USD Million)

10.1.1.4.2.2 Italy: Virology Market, by Viral Infection Controlling Techniques, 2019–2028 (USD Million)

10.1.1.4.2.3 Italy: Virology Market, by Antiviral Therapeutics, 2019–2028 (USD Million)

10.1.1.4.3 Italy Virology Market Revenue and Forecasts to 2028, by Application (US$ million)

10.1.1.4.4 Italy Virology Market Revenue and Forecasts to 2028, by End User (US$ million)

10.1.1.5 Spain Virology Market Revenue and Forecasts to 2028 (US$ million)

10.1.1.5.1 Spain Virology Market Revenue and Forecasts to 2028 (US$ million)

10.1.1.5.2 Spain Virology Market Revenue and Forecasts to 2028, By Type (US$ million)

10.1.1.5.2.1 Spain: Virology Market, by Diagnostic Test, 2019–2028 (USD Million)

10.1.1.5.2.2 Spain: Virology Market, by Viral Infection Controlling Techniques, 2019–2028 (USD Million)

10.1.1.5.2.3 Spain: Virology Market, by Antiviral Therapeutics, 2019–2028 (USD Million)

10.1.1.5.3 Spain Virology Market Revenue and Forecasts to 2028, by Application (US$ million)

10.1.1.5.4 Spain Virology Market Revenue and Forecasts to 2028, by End User (US$ million)

10.1.1.6 Rest of Europe Virology Market Revenue and Forecasts to 2028 (US$ million)

10.1.1.6.1 Rest of Europe Virology Market Revenue and Forecasts to 2028 (US$ million)

10.1.1.6.2 Rest of Europe Virology Market Revenue and Forecasts to 2028, By Type (US$ million)

10.1.1.6.2.1 Rest of Europe: Virology Market, by Diagnostic Test, 2019–2028 (USD Million)

10.1.1.6.2.2 Rest of Europe: Virology Market, by Viral Infection Controlling Techniques, 2019–2028 (USD Million)

10.1.1.6.2.3 Rest of Europe: Virology Market, by Antiviral Therapeutics, 2019–2028 (USD Million)

10.1.1.6.3 Rest of Europe Virology Market Revenue and Forecasts to 2028, by Application (US$ million)

10.1.1.6.4 Rest of Europe Virology Market Revenue and Forecasts to 2028, by End User (US$ million)

11. Impact of COVID-19 Pandemic on Europe Virology Market

11.1 Overview

12. Europe Virology Market–Industry Landscape

12.1 Overview

12.2 Organic Developments

12.2.1 Overview

12.3 Inorganic Developments

12.3.1 Overview

13. Company Profiles

13.1 Abbott

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

13.1.6 Key Developments

13.2 Johnson and Johnson Services, Inc.

13.2.1 Key Facts

13.2.2 Business Description

13.2.3 Products and Services

13.2.4 Financial Overview

13.2.5 SWOT Analysis

13.2.6 Key Developments

13.3 F. HOFFMANN-LA ROCHE LTD.

13.3.1 Key Facts

13.3.2 Business Description

13.3.3 Products and Services

13.3.4 Financial Overview

13.3.5 SWOT Analysis

13.3.6 Key Developments

13.4 THERMO FISHER SCIENTIFIC INC.

13.4.1 Key Facts

13.4.2 Business Description

13.4.3 Products and Services

13.4.4 Financial Overview

13.4.5 SWOT Analysis

13.4.6 Key Developments

13.5 QIAGEN

13.5.1 Key Facts

13.5.2 Business Description

13.5.3 Products and Services

13.5.4 Financial Overview

13.5.5 SWOT Analysis

13.5.6 Key Developments

13.6 Illumina, Inc.

13.6.1 Key Facts

13.6.2 Business Description

13.6.3 Products and Services

13.6.4 Financial Overview

13.6.5 SWOT Analysis

13.6.6 Key Developments

13.7 Siemens AG

13.7.1 Key Facts

13.7.2 Business Description

13.7.3 Products and Services

13.7.4 Financial Overview

13.7.5 SWOT Analysis

13.7.6 Key Developments

13.8 GlaxoSmithKline Plc

13.8.1 Key Facts

13.8.2 Business Description

13.8.3 Products and Services

13.8.4 Financial Overview

13.8.5 SWOT Analysis

13.8.6 Key Developments

13.9 AbbVie Inc.

13.9.1 Key Facts

13.9.2 Business Description

13.9.3 Products and Services

13.9.4 Financial Overview

13.9.5 SWOT Analysis

13.9.6 Key Developments

13.10 Gilead Sciences, Inc.

13.10.1 Key Facts

13.10.2 Business Description

13.10.3 Products and Services

13.10.4 Financial Overview

13.10.5 SWOT Analysis

13.10.6 Key Developments

14. Appendix

14.1 About The Insight Partners

14.2 Glossary of Terms

LIST OF TABLES

Table 1. Europe Virology Market Revenue and Forecast to 2028 (US$ Million)

Table 2. UK Virology Market Revenue and Forecasts to 2028, By Type US$ million)

Table 3. UK Virology Market, by Diagnostic Test– Revenue and Forecast to 2028 (USD Million)

Table 4. UK Virology Market, by Viral Infection Controlling Techniques– Revenue and Forecast to 2028 (USD Million)

Table 5. UK Virology Market, by Antiviral Therapeutics– Revenue and Forecast to 2028 (USD Million)

Table 6. UK Virology Market Revenue and Forecasts to 2028, by Application US$ million)

Table 7. UK Virology Market Revenue and Forecasts to 2028, by End User US$ million)

Table 8. Germany Virology Market Revenue and Forecasts to 2028, By Type (US$ million)

Table 9. Germany Virology Market, by Diagnostic Test– Revenue and Forecast to 2028 (USD Million)

Table 10. Germany Virology Market, by Viral Infection Controlling Techniques– Revenue and Forecast to 2028 (USD Million)

Table 11. Germany Virology Market, by Antiviral Therapeutics– Revenue and Forecast to 2028 (USD Million)

Table 12. Germany Virology Market Revenue and Forecasts to 2028, by Application US$ million)

Table 13. Germany Virology Market Revenue and Forecasts to 2028, by End User US$ million)

Table 14. France Virology Market Revenue and Forecasts to 2028, By Type (US$ million)

Table 15. France Virology Market, by Diagnostic Test– Revenue and Forecast to 2028 (USD Million)

Table 16. France Virology Market, by Viral Infection Controlling Techniques– Revenue and Forecast to 2028 (USD Million)

Table 17. France Virology Market, by Antiviral Therapeutics– Revenue and Forecast to 2028 (USD Million)

Table 18. France Virology Market Revenue and Forecasts to 2028, by Application (US$ million)

Table 19. France Virology Market Revenue and Forecasts to 2028, by End User (US$ million)

Table 20. Italy Virology Market Revenue and Forecasts to 2028, By Type (US$ million)

Table 21. Italy Virology Market, by Diagnostic Test– Revenue and Forecast to 2028 (USD Million)

Table 22. Italy Virology Market, by Viral Infection Controlling Techniques– Revenue and Forecast to 2028 (USD Million)

Table 23. Italy Virology Market, by Antiviral Therapeutics– Revenue and Forecast to 2028 (USD Million)

Table 24. Italy Virology Market Revenue and Forecasts to 2028, by Application (US$ million)

Table 25. Italy Virology Market Revenue and Forecasts to 2028, by End User (US$ million)

Table 26. Spain Virology Market Revenue and Forecasts to 2028, By Type (US$ million)

Table 27. Spain Virology Market, by Diagnostic Test– Revenue and Forecast to 2028 (USD Million)

Table 28. North America Virology Market, by Viral Infection Controlling Techniques– Revenue and Forecast to 2028 (USD Million)

Table 29. Spain Virology Market, by Antiviral Therapeutics– Revenue and Forecast to 2028 (USD Million)

Table 30. Spain Virology Market, by Application – Revenue and Forecast to 2028 by Application (USD Million)

Table 31. Spain Virology Market, by End User – Revenue and Forecast to 2028 by End User (USD Million)

Table 32. Rest of Europe Virology Market Revenue and Forecasts to 2028, By Type (US$ million)

Table 33. Rest of Europe Virology Market, by Diagnostic Test– Revenue and Forecast to 2028 (USD Million)

Table 34. Rest of Europe Virology Market, by Viral Infection Controlling Techniques– Revenue and Forecast to 2028 (USD Million)

Table 35. Rest of Europe Virology Market, by Antiviral Therapeutics– Revenue and Forecast to 2028 (USD Million)

Table 36. Rest of Europe Virology Market Revenue and Forecasts to 2028, by Application (US$ million)

Table 37. Rest of Europe Virology Market Revenue and Forecasts to 2028, by End User (US$ million)

Table 38. Organic Developments Done by Companies

Table 39. Inorganic Developments Done by Companies

Table 40. Glossary of Terms, Europe Virology Market

LIST OF FIGURES

Figure 1. Europe Virology Market Segmentation

Figure 2. Europe Virology Segmentation, By Country

Figure 3. Europe Virology Market Overview

Figure 4. Antiviral Therapeutics Held the Largest Share of the Type Segment in Europe Virology Market

Figure 5. Respiratory Tract Infections Held the Largest Share of the Application Segment in Europe Virology Market

Figure 6. UK to Show Significant Growth During Forecast Period

Figure 7. Europe and PEST Analysis

Figure 8. Europe Virology Market: Impact Analysis of Drivers and Restraints

Figure 9. Europe Virology Market– Revenue Forecast and Analysis – 2019- 2028

Figure 10. Europe Virology Market Revenue Share, by Type (2021 and 2028)

Figure 11. Europe Diagnostic Test: Virology Market – Revenue and Forecast to 2028 (US$ Million)

Figure 12. Europe DNA Virus Testing: Virology Market – Revenue and Forecast to 2028 (US$ Million)

Figure 13. Europe RNA Virus Testing: Virology Market – Revenue and Forecast to 2028 (US$ Million)

Figure 14. Europe Others: Virology Market – Revenue and Forecast to 2028 (US$ Million)

Figure 15. Europe Viral Infection Controlling Techniques: Virology Market – Revenue and Forecast to 2028 (US$ Million)

Figure 16. Europe Active Prophylaxis: Virology Market – Revenue and Forecast to 2028 (US$ Million)

Figure 17. Europe Passive Prophylaxis: Virology Market – Revenue and Forecast to 2028 (US$ Million)

Figure 18. Europe Antiviral Therapeutics : Virology Market – Revenue and Forecast to 2028 (US$ Million)

Figure 19. Europe Virucidal Agents: Virology Market – Revenue and Forecast to 2028 (US$ Million)

Figure 20. Europe Antiviral Agents: Virology Market – Revenue and Forecast to 2028 (US$ Million)

Figure 21. Europe Immunomodulators: Virology Market – Revenue and Forecast to 2028 (US$ Million)

Figure 22. Europe Interferons: Virology Market – Revenue and Forecast to 2028 (US$ Million)

Figure 23. Europe Virology Market, by Application 2021 & 2028 (%)

Figure 24. Europe Skin and Soft Tissue Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)

Figure 25. Europe Respiratory Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)

Figure 26. Europe GI Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)

Figure 27. Europe Sexually Transmitted Diseases: Virology Market – Revenue and Forecast to 2028 (US$ Million)

Figure 28. Europe Urinary Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)

Figure 29. Europe Others: Virology Market – Revenue and Forecast to 2028 (US$ Million)

Figure 30. Europe Virology Market Revenue Share, by End User (2021 and 2028)

Figure 31. Europe Hospitals: Virology Market – Revenue and Forecast to 2028 (US$ Million)

Figure 32. Europe Diagnostic Laboratories: Virology Market – Revenue and Forecast to 2028 (US$ Million)

Figure 33. Europe Pharmaceutical and Biotechnological Companies: Virology Market – Revenue and Forecast to 2028 (US$ Million)

Figure 34. Europe Research and Academic Institutes: Virology Market – Revenue and Forecast to 2028 (US$ Million)

Figure 35. Europe: Virology Market Revenue Overview, by Country, 2021 (US$ MN)

Figure 36. Europe Virology Market Revenue and Forecasts to 2028, By Country (%)

Figure 37. UK Virology Market Revenue and Forecasts to 2028 (US$ million)

Figure 38. Germany Virology Products Market Revenue and Forecasts to 2028 (US$ million)

Figure 39. France Virology Market Revenue and Forecasts to 2028 (US$ million)

Figure 40. Italy Virology Market Revenue and Forecasts to 2028 (US$ million)

Figure 41. Spain Virology Market Revenue and Forecasts to 2028 (US$ million)

Figure 42. Rest of Europe Virology Market Revenue and Forecasts to 2028 (US$ million)

Figure 43. Impact of COVID-19 Pandemic on Virology Market in European Countries

  1. Abbott
  2. AbbVie Inc.
  3. F. Hoffmann-La Roche Ltd.
  4. Gilead Sciences, Inc.
  5. GlaxoSmithKline Plc
  6. Illumina, Inc.
  7. Johnson and Johnson Services, Inc.
  8. QIAGEN
  9. Siemens AG
  10. Thermo Fisher Scientific Inc.

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Europe Virology Market